NASDAQ · MNOV

Medicinova, Inc.

$1.32 +$0.01 (+0.76%) 1D Market open

Key Metrics

$64.48M
Market cap
P/E · TTM
$596.64K
Revenue · TTM
−$11.72M
Net income
EPS · TTM $-0.24
Dividend yield
Free cash flow
Beta · 1Y 0.22
EBITDA · TTM −$11.61M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 12
    From its Jan 29 high, the share price fell 30%.

    Peak close $1.75 on Jan 29; trough close $1.23 on Jun 12. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -30%
  • Mar 20
    The stock moved +12.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 20
  • Mar 5
    The stock moved -9.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$64.48M
Enterprise value
Shares outstanding49.2M
52-wk range$1.17 – $1.96
Avg volume · 20D194.7K
Net cash
Book value / share$0.80
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Medicinova, Inc.
IPO dateDec 7, 2006
Employees6

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S108.07
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -1,948.5%
Net -1,964.3%
FCF
ROE / ROIC -25.5% · —

Financial Health

Current ratio9.09
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$25.05M

Cash Flow · TTM

Operating CF −$9.50M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-2.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings